ReviewFrontiers in pharmacology2020
Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 1 synthesis or guideline pooled it, 445 citations in OpenAlex.
- Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation.Fluids and barriers of the CNS · 2024Pooled it
- Cell-Penetrating Peptide Delivery for CRISPR Applications.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Targeted drug delivery systems for cardiovascular disease treatment: principles, targeting strategies, and future prospects.Annals of medicine · 2026Review
- Non-Covalent Active Mixing as a Viable Alternative to Covalent Conjugation for the Intracellular Delivery of Biologics: The Case of Glucarpidase.Applied biochemistry and biotechnology · 2026Article
- Protein Kinase C-delta (PKCδ) in Neurodegeneration and Cerebral Ischemia: Molecular Mechanisms and Therapeutic Implications.Cell biochemistry and biophysics · 2026Review
- Host nucleolin-targeting unique peptide drugs as potent broad-spectrum anti-influenza therapies.PNAS nexus · 2026Article
- Protein Modifications for Cellular Protein Delivery.Chemical reviews · 2026Review
- Intracellular protein binders for imaging, control and future therapeutics.Nature biomedical engineering · 2026Review
- Review
- CPP2Vec: A representation learning approach for cell-penetrating peptides prediction.PLoS computational biology · 2026Article
- Therapeutic peptides and proteins: Status and developments in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Polyproline Modulates Membrane Translocation of Arginine-Rich Cell-Penetrating Peptides: Insights from Molecular Dynamics Simulations.The Journal of membrane biology · 2026Article
- Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye.Translational vision science & technology · 2026Article
- The transmembrane segments of SARS-CoV-2 nsp3 govern viral intracellular trafficking.Cell & bioscience · 2026Article
- Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets.Nature communications · 2026Article
- Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins.Nature biotechnology · 2026Article
- Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles.Materials today. Bio · 2026Review
- Design of TAT-Conjugated Bowman-Birk Trypsin Inhibitor Peptides with Enhanced Antimicrobial and Antiproliferative Activities.Biomolecules · 2026Article
- Development of a quadruple-conjugated carbon dot nanomodel for targeted glioma therapy.Communications chemistry · 2026Article
- Developing antisense oligomer biotics "asobiotics" as precision antibacterials: designs, strategies, and considerations for future success.FEMS microbiology reviews · 2026Review
173 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have been predominantly used in basic and preclinical research during the last 30 years. Since they are not only capable of translocating themselves into cells but also facilitate drug or CPP/cargo complexes to translocate across the plasma membrane, they have potential applications in the disease diagnosis and therapy, including cancer, inflammation, central nervous system disorders, otologic and ocular disorders, and diabetes. However, no CPPs or CPP/cargo complexes have been approved by the US Food and Drug Administration (FDA). Many issues should be addressed before translating CPPs into clinics. In this review, we summarize recent developments and innovations in preclinical studies and clinical trials based on using CPP for improved delivery, which have revealed that CPPs or CPP-based delivery systems present outstanding diagnostic therapeutic delivery potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.